

# EXHIBIT A

Any question? -> Use the [BRENDA Discussion groups](#)

 **PRINT**

Mark a special word or phrase in this record:

Mark!

Select one or more organisms in this record:

All organisms  
Bos taurus  
Citrus macrophylla  
Cricetulus griseus  
Cytomegalovirus



Submit

Show additional data

☒ Do not include text mining results

Include **AMENDA** (text mining) results<sup>new!</sup> ([more...](#))

Include **FRENDA** results<sup>new!</sup> (AMENDA + additional results, but less precise; [more...](#))

 Please login to have access to the AMENDA and FRENDA data

## EC NUMBER COMMENTARY

2.4.1.65

### Pathway

### KEGG Link

Glycan structures - biosynthesis 2

[01031](#)

Glycosphingolipid biosynthesis - lactoseries

[00601](#)

Glycosphingolipid biosynthesis - neo-lactoseries

[00602](#)

## RECOMMENDED NAME

### GeneOntology No.

3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase

## SYSTEMATIC NAME

GDP-L-fucose:3-beta-D-galactosyl-N-acetyl-D-glucosaminy]l-R 4l-alpha-L-fucosyltransferase

### SYNONYMS

### ORGANISM

### COMMENTARY

### LITERATURE

(Lea)-dependent alpha-3/4-fucosyltransferase

-

-

-

alpha 1,3/4 fucosyltransferase

[Helicobacter pylori](#)

-

[662137](#)

alpha(1,3/1,4) fucosyltransferase III

-

-

-

alpha(1,3/4) fucosyltransferase

-

-

-

alpha-(1->4)-L-fucosyltransferase

-

-

-

alpha-1,3-fucosyltransferase

[Homo sapiens](#)

-

[661803](#)

alpha-1,3fucosyltransferase

[Homo sapiens](#)

-

[661277](#)

alpha-3-FUT

[Gorilla gorilla](#)

-

[661839](#)

alpha-3-FUT

[Homo sapiens](#)

-

[661839](#)

alpha-3/4 fucosyltransferase

[Homo sapiens](#)

-

[662484](#)

alpha-3/4 fucosyltransferase III

[Homo sapiens](#)

-

[661313](#)

alpha-3/4 fucosyltransferase III

[Mesocricetus auratus](#)

-

[661236](#)

alpha-3/4-FUT

[Gorilla gorilla](#)

-

[661839](#)

alpha-3/4-FUT	<u>Homo sapiens</u>	•	<u>661839</u>
alpha-3/4-FUT	<u>Hylobates lar</u>	-	<u>661839</u>
alpha-3/4-FUT	<u>Pongo pygmaeus</u>	-	<u>661839</u>
alpha-4-fucosyltransferase	<u>Silene alba</u>	-	<u>661845</u>
alpha-4-L-fucosyltransferase	-	-	-
alpha4-fucosyltransferase	-	-	-
alpha4-FucT	-	-	-
beta-acetylglucosaminylsaccharide fucosyltransferase	-	-	-
blood group Lewis alpha-4-fucosyltransferase	-	-	-
blood-group substance Lea-dependent fucosyltransferase	-	-	-
FT3	<u>Homo sapiens</u>	-	<u>662484</u>
FT3	<u>Mesocricetus auratus</u>	-	<u>661236</u>
Fuc-T	<u>Homo sapiens</u>	-	<u>661341</u>
Fuc-TIII	-	-	-
fucosyltransferase	<u>Homo sapiens</u>	-	<u>661433</u>
fucosyltransferase 3	<u>Homo sapiens</u>	•	<u>661839</u>
fucosyltransferase 3	<u>Pongo pygmaeus</u>	-	<u>661839</u>
fucosyltransferase 5	<u>Gorilla gorilla</u>	-	<u>661839</u>
fucosyltransferase 5	<u>Homo sapiens</u>	-	<u>661839</u>
fucosyltransferase 5	<u>Hylobates lar</u>	-	<u>661839</u>
fucosyltransferase 5	<u>Pongo pygmaeus</u>	-	<u>661839</u>
fucosyltransferase 6	<u>Gorilla gorilla</u>	-	<u>661839</u>
fucosyltransferase 6	<u>Homo sapiens</u>	-	<u>661839</u>
fucosyltransferase 7	<u>Homo sapiens</u>	-	<u>660797</u>
fucosyltransferase V	<u>Homo sapiens</u>	•	<u>661341</u>
fucosyltransferase VII	<u>Homo sapiens</u>	-	<u>660797</u>
fucosyltransferase, guanosine diphosphofucose-beta-acetylglucosaminylsaccharide 4-alpha-L-	-	•	-
fucosyltransferase, guanosine diphosphofucose-glycoprotein 4-alpha-	-	-	-
FucT	<u>Helicobacter pylori</u>	-	<u>662137</u>
FucT	<u>Homo sapiens</u>	-	<u>661277</u> , <u>661803</u>
FucT	<u>Silene alba</u>	-	<u>661845</u>
FucT VII	<u>Homo sapiens</u>	-	<u>660797</u>
FucT-II	-	-	-
FucT-III	<u>Homo sapiens</u>	-	<u>661839</u>
FucT-III	<u>Pongo pygmaeus</u>	-	<u>661839</u>
FucT-V	<u>Gorilla gorilla</u>	-	<u>661839</u>
FucT-V	<u>Homo sapiens</u>	-	<u>661839</u>
FucT-V	<u>Hylobates lar</u>	-	<u>661839</u>

FucT-V	<u>Pongo pygmaeus</u>	-	<u>661839</u>
FucT-VI	<u>Gorilla gorilla</u>	-	<u>661839</u>
FucT-VI	<u>Homo sapiens</u>	-	<u>661839</u>
FucT-VII	<u>Homo sapiens</u>	-	<u>660797</u>
FucTIII	-	-	-
FUT3	-	-	-
guanosine diphosphofucose-glycoprotein 4-alpha-L-fucosyltransferase	-	-	-
Lewis alpha-3-fucosyltransferase	<u>Gorilla gorilla</u>	FUT6 gene	<u>661839</u>
Lewis alpha-3-fucosyltransferase	<u>Homo sapiens</u>	FUT6 gene	<u>661839</u>
Lewis alpha-3/4-fucosyltransferase	-	-	-
Lewis alpha-3/4-fucosyltransferase	<u>Gorilla gorilla</u>	FUT5 gene	<u>661839</u>
Lewis alpha-3/4-fucosyltransferase	<u>Homo sapiens</u>	FUT3 gene; FUT5 gene	<u>661839</u>
Lewis alpha-3/4-fucosyltransferase	<u>Hylobates lar</u>	FUT5 gene	<u>661839</u>
Lewis alpha-3/4-fucosyltransferase	<u>Pongo pygmaeus</u>	FUT3 gene; FUT5 gene	<u>661839</u>
Lewis alpha1-3/4 fucosyltransferase	-	-	-
Lewis blood group alpha1-3/4 fucosyltransferase	-	-	-
Lewis(Le) blood group gene-dependent alpha-3/4-L-fucosyltransferase	-	-	-
More	-	-	-
SFT3	-	-	-
SFT3	<u>Homo sapiens</u>	-	<u>661313</u>
SFT3	<u>Homo sapiens</u>	secretory soluble form of FT3	<u>662484</u>

## CAS REGISTRY NUMBER COMMENTARY

37277-69-3

## REACTION

GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R = GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
















## COMMENTARY ORGANISM LITERATURE















REACTION TYPE	ORGANISM	COMMENTARY	LITERATURE
hexosyl group transfer	-	-	-
hexosyl group transfer	<u>Mesocricetus auratus</u>	-	<u>661236</u>
hexosyl group transfer	<u>Silene alba</u>	-	<u>661845</u>
hexosyl group transfer	<u>Helicobacter pylori</u>	-	<u>662137</u>
hexosyl group transfer	<u>Pongo pygmaeus</u>	-	<u>661839</u>
hexosyl group transfer	<u>Hylobates lar</u>	-	<u>661839</u>

hexosyl group transfer	<u>Homo sapiens</u>	-	<u>661277, 661313, 661341, 661803, 662484, 661433, 661839, 660797</u>
hexosyl group transfer	<u>Gorilla gorilla</u>	-	<u>661839</u>
















ORGANISM	COMMENTARY	LITERATURE	SEQUENCE CODE	SOURCE
<u>Bos taurus</u>	-	<u>637650</u>	SwissprotQ11126	BRENDA
<u>Bos taurus</u>	Swiss-Prot	-	Q11126	BRENDA
<u>Gorilla gorilla</u>	-	<u>661839</u>	Q8HYJ6	BRENDA
<u>Gorilla gorilla</u>	-	<u>661839</u>	Q8HYJ7	BRENDA
<u>Gorilla gorilla gorilla</u>	Swiss-Prot	-	Q8HYJ6	BRENDA
<u>Gorilla gorilla gorilla</u>	Swiss-Prot	-	Q8HYJ7	BRENDA
<u>Helicobacter pylori</u>	-	<u>637638</u>	-	BRENDA
<u>Helicobacter pylori</u>	-	<u>662137</u>	Q9L8S4	BRENDA
<u>Homo sapiens</u>	-	<u>637634, 637635, 637636, 637637, 637640, 637641, 637642, 637643, 637644, 637647, 637648, 661313, 661341, 661803, 662484, 637645, 637646, 661277</u>	-	BRENDA
<u>Homo sapiens</u>	-	<u>637651, 637652, 637653, 637654, 637655, 637656, 637657, 637658, 637659, 637660</u>	SwissprotP21217	BRENDA
<u>Homo sapiens</u>	-	<u>660797</u>	Q11130	BRENDA
<u>Homo sapiens</u>	-	<u>661433, 661839</u>	P51993	BRENDA
<u>Homo sapiens</u>	-	<u>661433, 661839</u>	Q11128	BRENDA
<u>Homo sapiens</u>	-	<u>661839</u>	P21217	BRENDA
<u>Homo sapiens</u>	Swiss-Prot	-	P21217	BRENDA
<u>Homo sapiens</u>	Swiss-Prot	-	P51993	BRENDA
<u>Homo sapiens</u>	Swiss-Prot	-	Q11128	BRENDA
<u>Hylobates lar</u>	-	<u>661839</u>	Q8HYJ3	BRENDA
<u>Hylobates lar</u>	Swiss-Prot	-	Q8HYJ3	BRENDA
<u>Macaca mulatta</u>	-	<u>637642</u>	-	BRENDA
<u>Mesocricetus auratus</u>	-	<u>661236</u>	-	BRENDA
<u>Pan troglodytes</u>	-	<u>637649</u>	SwissprotO19058	BRENDA
<u>Pan troglodytes</u>	Swiss-Prot	-	Q19058	BRENDA
<u>Pan troglodytes</u>	Swiss-Prot	-	P56433	BRENDA
<u>Pan troglodytes</u>	Swiss-Prot	-	P56434	BRENDA
<u>Physcomitrella patens</u>	TrEMBL	-	Q5TJK3	BRENDA
<u>Pongo pygmaeus</u>	-	<u>661839</u>	Q8HYJ4	BRENDA
<u>Pongo pygmaeus</u>	-	<u>661839</u>	Q8HYJ5	BRENDA
<u>Pongo pygmaeus</u>	Swiss-Prot	-	Q8HYJ4	BRENDA
<u>Pongo pygmaeus</u>	Swiss-Prot	-	Q8HYJ5	BRENDA
<u>Pongo pygmaeus</u>	Swiss-Prot	-	Q9GKU6	BRENDA
<u>Populus tremula x Populus alba</u>	TrEMBL	-	Q599J3	BRENDA
<u>Rattus norvegicus</u>	-	<u>489362</u>	-	BRENDA

<b>Silene alba</b>	-	<b>661845</b>	-	<b>BRENDA</b>
<b>Vaccinium myrtillus</b>	-	<b>637636</b>	-	<b>BRENDA</b>









SUBSTRATE	PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY/ Substrate r:=reversible ir:=irreversible	LITERATURE/ Substrate	COMME Product
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc	GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,4)GlcNAc		<u>Homo sapiens</u>	17.6% activity	<a href="#">661433</a>	-
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc	GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,4)GlcNAc		<u>Homo sapiens</u>	19.4% activity	<a href="#">661433</a>	-
GDP-fucose + 2-O-MeGal-beta-1,4GlcNAc	GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,3)GlcNAc		<u>Homo sapiens</u>	100% activity	<a href="#">661433</a>	-
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein	GDP + ?		<u>Homo sapiens</u>	42.9% activity	<a href="#">661433</a>	-
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein	GDP + ?		<u>Homo sapiens</u>	5.2% activity	<a href="#">661433</a>	-
GDP-fucose + Fetuin triantennary asialo glycoprotein	GDP + ?		<u>Homo sapiens</u>	36.9% activity	<a href="#">661433</a>	-
GDP-fucose + Fetuin triantennary asialo glycoprotein	GDP + ?		<u>Homo sapiens</u>	73.8% activity	<a href="#">661433</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-O-C6H5	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-O-C6H5		<u>Silene alba</u>	H-type 1 reaction	<a href="#">661845</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin		<u>Gorilla gorilla</u>	type 1 reaction	<a href="#">661839</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin		<u>Homo sapiens</u>	type 1 reaction	<a href="#">661839</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin		<u>Hylobates lar</u>	type 1 reaction	<a href="#">661839</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin		<u>Pongo pygmaeus</u>	type 1 reaction	<a href="#">661839</a>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin		<u>Silene alba</u>	H-type 2 reaction, hardly any activity	<a href="#">661845</a>	-





beta-1,4GlcNAc-O-C6H5	alpha-1,3)GlcNAc-O-C6H5					
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin		<u>Gorilla gorilla</u>	type 2 reaction	<u>661839</u>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin		<u>Homo sapiens</u>	type 2 reaction	<u>661839</u>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin		<u>Hylobates lar</u>	type 2 reaction	<u>661839</u>	-
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin		<u>Pongo pygmaeus</u>	type 2 reaction	<u>661839</u>	-
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3	GDP + Gal-beta-1,3 [alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3		<u>Helicobacter pylori</u>	type 1 reaction, chimeric FucT 11639 (347CNDHYSALH)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3	GDP + Gal-beta-1,3 [alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3		<u>Helicobacter pylori</u>	type 1 reaction, chimeric FucT UA948 (1-360)11639(360-478)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3	GDP + Gal-beta-1,3 [alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3		<u>Helicobacter pylori</u>	type 1 reaction, chimeric FucT UA948 (345DNPFIFC)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3	GDP + Gal-beta-1,3 [alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3		<u>Helicobacter pylori</u>	type 1 reaction, strain UA948	<u>662137</u>	-
GDP-fucose + Gal-beta-1,3GlcNAc	GDP + Gal-beta-1,3 (Fuc-alpha-1,4)GlcNAc		<u>Homo sapiens</u>	-	<u>661277</u>	-
GDP-fucose + Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc	GDP + Gal-beta-1,3 (Fuc-alpha-1,4)GlcNAc-beta-1,3Gal-beta-1,4Glc		<u>Homo sapiens</u>	-	<u>661277</u>	-
GDP-fucose + Gal-beta-1,3GlcNAc-beta-O-(CH2)7CH3	GDP + Gal-beta-1,3 (Fuc-alpha-1,4)GlcNAc-beta-O-(CH2)7CH3		<u>Silene alba</u>	type 1 reaction	<u>661845</u>	-
GDP-Fucose + Gal-beta-1,3GlcNAc-O(CH2)3NHCO(CH2)5NH-biotin	GDP + Gal-beta-1,3 [alpha-L-fucosyl-(1,4)] GlcNAcO(CH2)3NHCO(CH2)5NH-biotin		<u>Mesocricetus auratus</u>	-	<u>661236</u>	-
GDP-fucose + Gal-beta-1,3GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin	GDP + Gal-beta-1,3 (Fuc-alpha-1,4)GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin		<u>Homo sapiens</u>	-	<u>662484</u>	-
GDP-fucose + Gal-beta-1,3GlcNAcO(CH2)3NHCO	GDP + Gal-beta-1,3 [alpha-L-fucosyl-(1,4)] GlcNAcO(CH2)3NHCO(CH2)5NH-biotin		<u>Homo sapiens</u>	-	<u>661313</u>	-





(CH<sub>2</sub>)<sub>5</sub>NH-biotin











GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, chimeric FucT 11639(1- 359)UA948(361-462)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, chimeric FucT 11639 (347CND AHYSALH)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, chimeric FucT UA948 (1-360)11639(360-478)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, chimeric FucT UA948 (345DNPFIFC)	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, strain NCTC116639	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4- GlcNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>	GDP + Gal-beta-1,4 [alpha-fucosyl(1,3)]- GLCNAc-O-(CH <sub>2</sub> ) 8CO <sub>2</sub> CH <sub>3</sub>		<u>Helicobacter pylori</u>	type 2 reaction, strain UA948	<u>662137</u>	-
GDP-fucose + Gal-beta-1,4Glc	GDP + Gal-beta-1,4 (Fuc-alpha-1,3)Glc		<u>Homo sapiens</u>	-	<u>661277</u>	-
GDP-fucose + Gal-beta- 1,4GlcNAc	GDP + Gal-beta-1,4 (Fuc-alpha-1,3)GlcNAc + Gal-beta-1,4(Fuc- alpha-1,2)GlcNAc		<u>Homo sapiens</u>	enzyme activity is divided into 66% alpha- 1,3FucT and 34% alpha-1,2FucT	<u>661277</u>	-
GDP-fucose + Gal-beta- 1,4GlcNAc-beta- 1-R	GDP + Gal-beta-1,4 (fuc-alpha-1,3)GlcNAc- beta-1-R		<u>Homo sapiens</u>	-	<u>661341</u>	-
GDP-fucose + Gal-beta- 1,4GlcNAc-beta- O-(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	GDP + Gal-beta-1,3 (Fuc-alpha-1,3)GlcNAc- beta-O-(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>		<u>Silene alba</u>	type 2 reaction, hardly any activity	<u>661845</u>	-
GDP-fucose + GalNAc-beta- 1,4GlcNAc-beta- O-Bn	GDP + GalNAc-beta-1,4 (Fuc-alpha-1,3)GlcNAc- beta-O-Bn		<u>Homo sapiens</u>	91.9% activity	<u>661433</u>	-
GDP-fucose + GalNAc-beta- 1,4GlcNAc-beta- O-Bn	GDP + GalNAc-beta-1,4 (Fuc-alpha-1,3)GlcNAc- beta-O-Bn		<u>Homo sapiens</u>	95.0% activity	<u>661433</u>	-
GDP-fucose + GlcNAc-beta- 1,4GlcNAc-beta- 1,4GlcNAc	?		<u>Homo sapiens</u>	activity not determined	<u>661433</u>	-
GDP-fucose + GlcNAc-beta- 1,4GlcNAc-beta- 1,4GlcNAc	GDP + ?		<u>Homo sapiens</u>	63.8% activity	<u>661433</u>	-
GDP-fucose + GlcNAc-beta- 1,4GlcNAc-beta- 1,4GlcNAc-beta-	?		<u>Homo sapiens</u>	activity not determined	<u>661433</u>	-
























1,4GlcNAc						
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc	GDP + ?		<u>Homo sapiens</u>	61.5% activity	<u>661433</u>	-
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn	GDP + GlcNAc-beta-1,4 (Fuc-alpha-1,3)GlcNAc-beta-O-Bn		<u>Homo sapiens</u>	11.3% activity	<u>661433</u>	-
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn	GDP + GlcNAc-beta-1,4 (Fuc-alpha-1,3)GlcNAc-beta-O-Bn		<u>Homo sapiens</u>	89.1% activity	<u>661433</u>	-
GDP-fucose + LacNAc	?		<u>Homo sapiens</u>	-	<u>661803</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<u>Helicobacter pylori</u>	inactivation of the enzyme eliminates expression of all Lewis antigens	<u>637638</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<u>Homo sapiens</u>	the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation	<u>637637</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637651</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637652</u>	-














GDP-L-fucose + 1,3-beta-D- galactosyl-N- acetyl-D- glucosaminyI-R	GDP + 1,3-beta-D- galactosyl-(alpha-(1,4)- L-fucosyl)-N-acetyl-D- glucosaminyI-R 	<u>Homo</u> <u>sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis- positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637653</u>	-
GDP-L-fucose + 1,3-beta-D- galactosyl-N- acetyl-D- glucosaminyI-R	GDP + 1,3-beta-D- galactosyl-(alpha-(1,4)- L-fucosyl)-N-acetyl-D- glucosaminyI-R 	<u>Homo</u> <u>sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis- positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637654</u>	-
GDP-L-fucose + 1,3-beta-D- galactosyl-N- acetyl-D- glucosaminyI-R	GDP + 1,3-beta-D- galactosyl-(alpha-(1,4)- L-fucosyl)-N-acetyl-D- glucosaminyI-R 	<u>Homo</u> <u>sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis- positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637655</u>	-
GDP-L-fucose + 1,3-beta-D- galactosyl-N- acetyl-D- glucosaminyI-R	GDP + 1,3-beta-D- galactosyl-(alpha-(1,4)- L-fucosyl)-N-acetyl-D- glucosaminyI-R 	<u>Homo</u> <u>sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis- positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637656</u>	-
GDP-L-fucose +	GDP + 1,3-beta-D-	Homo	the enzyme may	<u>637657</u>	-















1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R 	<u>sapiens</u>	catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme		
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R 	<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637658</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R 	<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637659</u>	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R 	<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637660</u>	-
GDP-L-fucose + 1,3-beta-D-	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-	<u>Pan troglodytes</u>	the enzyme may catalyze alpha-1,3 and	<u>637649</u>	-

galactosyl-N-acetyl-D-glucosaminyI-R	L-fucosyl)-N-acetyl-D-glucosaminyI-R			alpha-1,4 glycosidic linkages involved in expression of sialyl Lewis X and Lewis X/SSEA-1 antigens. It may be involved in blood group Lewis determination		
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<i>Helicobacter pylori</i>	the enzyme appears to add fucose with a greater than 5fold preference for type II chains but still retains significant activity using type I acceptors. The addition of fucose to type II acceptors does not appear to be affected by fucosylation at other sites on the carbohydrate acceptor	637638	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<i>Homo sapiens</i>		637636	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<i>Homo sapiens</i>	the enzyme has a clear preference for the Galbeta3GlcNAc motif in oligosaccharides conjugated with the hydrophobic tail (CH <sub>2</sub> ) <sub>3</sub> -NHCO-(CH <sub>2</sub> ) <sub>5</sub> -NH-biotin	637637	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyI-R	GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyI-R		<i>Vaccinium myrtillus</i>	transfer of fucose to N-acetylglucosamine in the type I Galbeta3GlcNAc motif from oligosaccharides linked to a hydrophobic tail and glycoproteins containing the type I motif. Sialylated oligosaccharides containing the type II Galbeta4GlcNAc motif are not acceptors	637636	-
GDP-L-fucose + 2'-fucosyllactose	GDP + ?		<i>Homo sapiens</i>		637634	-
GDP-L-fucose + 2'-fucosyllactose	GDP + ?		<i>Homo sapiens</i>	11% of the activity with Fucalpa(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc	637635	-
GDP-L-fucose + 2'-fucosyllactose	GDP + ?		<i>Homo sapiens</i>	254% of the activity with Galbeta(1,4)GlcNAc	637644	-
GDP-L-fucose + 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn	GDP + 2-O-MeGalbeta(1,3)(Fucalpa(1,4))GlcNAcbeta-O-Bn		<i>Homo sapiens</i>		637647	-
GDP-L-fucose + 3-O-MeGalbeta	GDP + 3-O-MeGalbeta(1,4)(Fucalpa(1,3))		<i>Homo sapiens</i>	16.3% of the activity with 2-O-MeGalbeta	637647	-











(1,4)GlcNAcbeta (1,6)(Galbeta (1,3)) GalNAcalpha-O- Bn	GlcNAcbeta(1,6) (Galbeta(1,3)) GalNAcalpha-O-Bn			(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 17.8% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTB		
GDP-L-fucose + 3-O-sulfoGalbeta (1,3)GlcNAcbeta (1,3)Galbeta-O-Al	GDP + 3-O- sulfoGalbeta(1,3) (Fucalalpha(1,4)) GlcNAcbeta(1,3) Galbeta-O-Al		<u>Homo sapiens</u>	64.3% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 82.2% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + 3-O-sulfoGalbeta (1,3)GlcNAcbeta- O-Al	GDP + 3-O- sulfoGalbeta(1,3) (Fucalalpha(1,4)) GlcNAcbeta-O-Al		<u>Homo sapiens</u>	64.3% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 62.9% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + 3-O-sulfoGalbeta (1,4)GlcNAcbeta (1,6)(Galbeta (1,3)) GalNAcalpha-O- Bn	GDP + 3-O- sulfoGalbeta(1,4) (Fucalalpha(1,3)) GlcNAcbeta(1,6) (Galbeta(1,3)) GalNAcalpha-O-Bn		<u>Homo sapiens</u>	10.9% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 14.0% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + 6-O-sulfoGalbeta (1,3)GlcNAcbeta- O-Al	GDP + 6-O- sulfoGalbeta(1,3) (Fucalalpha(1,4)) GlcNAcbeta-O-Al		<u>Homo sapiens</u>	3.1% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + alpha(2,3)- sialyllactosamine	GDP + ?		<u>Homo sapiens</u>	56% of the activity with Galbeta(1,4)GlcNAc	<u>637644</u>	-
GDP-L-fucose + alpha-(2,3)- sialylated Galbeta(1,3) GlcNAc	GDP + ?		<u>Rattus norvegicus</u>	-	<u>489362</u>	-
GDP-L-fucose + ancrod	GDP + ?		<u>Homo sapiens</u>	-	<u>637647</u>	-
GDP-L-fucose + asialo ancrod	GDP + ?		<u>Homo sapiens</u>	-	<u>637647</u>	-
GDP-L-fucose + asialofetuin	GDP + ?		<u>Homo sapiens</u>	-	<u>637636</u>	-
GDP-L-fucose + asialofetuin	GDP + ?		<u>Homo sapiens</u>	no activity	<u>637637</u>	-
GDP-L-fucose + asialofetuin	GDP + ?		<u>Homo sapiens</u>	the acceptor oligosaccharide in bovine asialofetuin is the man3 branched triantennary isomer with one Galbeta(1,3)	<u>637648</u>	-














GDP-L-fucose + asialofetuin	GDP + ?		<u>Vaccinium myrtillus</u>	GlcNAc 7.3% of the activity with Galbeta3GlcNAc-O-sp- biotin	<u>637636</u>	-
GDP-L-fucose + fetuin triantennary glycopeptide	GDP + ?		<u>Homo sapiens</u>	-	<u>637647</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAc		<u>Homo sapiens</u>	activity of the wild-type enzyme is about 3% of the activity with Fucalpha(1,2)Galbeta (1,4)GlcNAc. The mutation W111R shows higher activity for Fucalpha(1,2)Galbeta (1,3)GlcNAc than for Fucalpha(1,2)Galbeta (1,4)GlcNAc. The addition mutation in W111R/D112E increases activity for Fucalpha(1,2)Galbeta (1,3)GlcNAc compared to mutant W111R	<u>637646</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc-(CH2)3- NHCO-(CH2)5- NH-biotin	GDP + ?		<u>Homo sapiens</u>	-	<u>637643</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc-(CH2)5- NH-biotin	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAc-(CH2)5- NH-biotin		<u>Homo sapiens</u>	193% of the activity with Galbeta(1,3) GlcNAc-(CH2)3-NHCO- (CH2)5-NH-biotin	<u>637637</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc-O-sp- biotin	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAc-O-sp- biotin		<u>Vaccinium myrtillus</u>	118% of the activity with Galbeta3GlcNAc- O-sp-biotin	<u>637636</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc-R	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAc-R		<u>Homo sapiens</u>	-	<u>637642</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAc-R	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAc-R		<u>Macaca mulatta</u>	-	<u>637642</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,3) GlcNAcbeta(1,3) Galbeta(1,4)Glc	GDP + Fucalpha(1,2) Galbeta(1,3)(Fucalpha (1,4))GlcNAcbeta(1,3) Galbeta(1,4)Glc		<u>Homo sapiens</u>	i.e. lacto-N- fucopentaose I	<u>637635</u>	-
GDP-L-fucose + Fucalpha(1,2) Galbeta(1,4)Glc	GDP + Fucalpha(1,2) Galbeta(1,4)(Fucalpha (1,3))Glc		<u>Homo sapiens</u>	34.9% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 38.7% of the activity with 2-O-MeGalbeta (1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-








GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc	GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc		<u>Homo sapiens</u>	-	<u>637646</u>	-
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc	GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc		<u>Homo sapiens</u>	mutant enzyme D336A shows 40fold reduction in activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc	<u>637645</u>	-
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin		<u>Homo sapiens</u>	3% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells	<u>637643</u>	-
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)5-NH-biotin	GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)5-NH-biotin		<u>Homo sapiens</u>	9.3% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	<u>637637</u>	-
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-O-sp-biotin	GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-O-sp-biotin		<u>Vaccinium myrtillus</u>	10.5% of the activity with Galbeta3GlcNAc-O-sp-biotin	<u>637636</u>	-
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R	GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R		<u>Homo sapiens</u>	-	<u>637642</u>	-
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R	GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R		<u>Macaca mulatta</u>	-	<u>637642</u>	-
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAcbeta-O-Naph	GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Naph		<u>Homo sapiens</u>	42.6 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 46.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + Galbeta(1,3)(6-O-sulfo)GlcNAcbeta(1,3)Galbeta-O-Al	GDP + ?		<u>Homo sapiens</u>	15.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 19.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	-	<u>637640</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	-	<u>637645</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	130% of the activity with Galbeta(1,4)GlcNAc	<u>637634</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	29% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)	<u>637635</u>	-







GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	Galbeta(1,4)Glc 420% of the activity with Galbeta(1,4)GlcNAc	<u>637644</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc		<u>Homo sapiens</u>	45.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 51% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin		<u>Homo sapiens</u>	-	<u>637637</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin		<u>Homo sapiens</u>	-	<u>637643</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc-O-sp-biotin	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-O-sp-biotin		<u>Vaccinium myrtillus</u>	-	<u>637636</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc-R	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R		<u>Homo sapiens</u>	-	<u>637642</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAc-R	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R		<u>Macaca mulatta</u>	-	<u>637642</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc		<u>Homo sapiens</u>	20% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc	<u>637635</u>	-
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta-O-Bn	GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn		<u>Homo sapiens</u>	79.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 83.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + Galbeta(1,4)-(5-thioGlc)	GDP + ?		<u>Homo sapiens</u>	51% of the activity with Galbeta(1,4)GlcNAc	<u>637634</u>	-
GDP-L-fucose + Galbeta(1,4)Glc	GDP + Galbeta(1,4)(Fucalpha(1,3))Glc		<u>Homo sapiens</u>	-	<u>637634</u>	-
GDP-L-fucose + Galbeta(1,4)Glc	GDP + Galbeta(1,4)(Fucalpha(1,3))Glc		<u>Homo sapiens</u>	145% of the activity with Galbeta(1,4)GlcNAc	<u>637644</u>	-
GDP-L-fucose + Galbeta(1,4)Glc	GDP + Galbeta(1,4)(Fucalpha(1,3))Glc		<u>Homo sapiens</u>	i.e. lactose, 2% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc	<u>637635</u>	-
GDP-L-fucose + Galbeta(1,4)	GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc		<u>Homo sapiens</u>	3.9% of the activity with 2-O-MeGalbeta(1,3)	<u>637647</u>	-









<b>GlcNAc</b>					GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB		
GDP-L-fucose + Galbeta(1,4) GlcNAc	GDP + Galbeta(1,4) (Fucalpa(1,3))GlcNAc		<b>Homo sapiens</b>	43% of the activity with Fucalpa(1,2)Galbeta (1,3)GlcNAcbeta(1,3) Galbeta(1,4)Glc	<b>637635</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAc	GDP + Galbeta(1,4) (Fucalpa(1,3))GlcNAc		<b>Homo sapiens</b>	i.e. N- acetylactosamine	<b>637640</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAc-(CH2)3- NHCO-(CH2)5- NH-biotin	GDP + Galbeta(1,4) (Fucalpa(1,3))GlcNAc- (CH2)3-NHCO-(CH2)5- NH-biotin		<b>Homo sapiens</b>	2% of the activity with Galbeta(1,3)GlcNAc- (CH2)3-NHCO-(CH2)5- NH-biotin, enzyme expressed in Sf9 cells	<b>637643</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta(1,2) Man	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,2)Man		<b>Homo sapiens</b>	28% of the activity with Fucalpa(1,2)Galbeta (1,3)GlcNAcbeta(1,3) Galbeta(1,4)Glc	<b>637635</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta(1,3) Galbeta(1,4)Glc	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,3) Galbeta(1,4)Glc		<b>Homo sapiens</b>	33% of the activity with Fucalpa(1,2)Galbeta (1,3)GlcNAcbeta(1,3) Galbeta(1,4)Glc	<b>637635</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta(1,6) (3-O-MeGalbeta (1,3)) GalNAcalpha-O- Bn	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,6)(3-O- MeGalbeta(1,3)) GalNAcalpha-O-Bn		<b>Homo sapiens</b>	2.3% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 1.9% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<b>637647</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta(1,6) (3-O-sulfoGalbeta (1,3))- GalNAcalpha-O- Bn	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,6)(3-O- sulfoGalbeta(1,3))- GalNAcalpha-O-Bn		<b>Homo sapiens</b>	1.6% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<b>637647</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta(1,6) (Galbeta(1,3)) GalNAcalpha-O- Bn	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,6) (Galbeta(1,3)) GalNAcalpha-O-Bn		<b>Homo sapiens</b>	2.3% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<b>637647</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbeta-O- Bn	GDP + Galbeta(1,4) (Fucalpa(1,4)) GlcNAcbeta-O-Bn		<b>Homo sapiens</b>	3.1% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 2.5% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<b>637647</b>	-	
GDP-L-fucose + Galbeta(1,4) GlcNAcbetaOallyl	GDP + Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbetaOallyl		<b>Homo sapiens</b>	64% of the activity with Galbeta(1,4)GlcNAc	<b>637634</b>	-	

GDP-L-fucose + Galbeta(1,4) Glucal	GDP + Galbeta(1,4) (Fucalpa(1,3))Glucal		<u>Homo sapiens</u>	10% of the activity with Galbeta(1,4)GlcNAc	<u>637634</u>	-
GDP-L-fucose + Galbeta(1,6) Galbeta(1,4)Glc	GDP + ?		<u>Homo sapiens</u>	-	<u>637635</u>	-
GDP-L-fucose + GalNAcbeta(1,3) (6-O-sulfo) GlcNAcbeta-O-Me	GDP + ?		<u>Homo sapiens</u>	6.2 of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTA. 8.6% of the activity with 2-O-MeGalbeta(1,3) GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + IL-4 receptor	GDP + ?		<u>Homo sapiens</u>	-	<u>637648</u>	-
GDP-L-fucose + lacto-N-fucopentaose	GDP + ?		<u>Homo sapiens</u>	-	<u>637634</u>	-
GDP-L-fucose + NeuAc(2,3) Galbeta(1,4) Glucal	GDP + NeuAc(2,3) Galbeta(1,4)(Fucalpa(1,3))Glucal		<u>Homo sapiens</u>	330% of the activity with Galbeta(1,4) GlcNAc	<u>637634</u>	-
GDP-L-fucose + NeuAc(2,6) Galbeta(1,4) GlcNAc	GDP + NeuAc(2,6) Galbeta(1,4)(Fucalpa(1,3))GlcNAc		<u>Homo sapiens</u>	13% of the activity with Galbeta(1,4)GlcNAc	<u>637634</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,3) GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	GDP + NeuAcalpha(2,3)Galbeta(1,3) (Fucalpa(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin		<u>Homo sapiens</u>	-	<u>637643</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,3) GlcNAc-(CH2)5-NH-biotin	GDP + NeuAcalpha(2,3)Galbeta(1,3) (Fucalpa(1,4))GlcNAc-(CH2)5-NH-biotin		<u>Homo sapiens</u>	57% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	<u>637637</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,3) GlcNAcbeta-O-Bn	GDP + NeuAcalpha(2,3)Galbeta(1,3) (Fucalpa(1,4)) GlcNAcbeta-O-Bn		<u>Homo sapiens</u>	55.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 64.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,4) GlcNAc	GDP + NeuAcalpha(2,3)Galbeta(1,4) (Fucalpa(1,3))GlcNAc		<u>Homo sapiens</u>	620% of the activity with Galbeta(1,4) GlcNAc	<u>637634</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,4) GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin	GDP + NeuAcalpha(2,3)Galbeta(1,4) (Fucalpa(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin		<u>Homo sapiens</u>	-	<u>637643</u>	-
GDP-L-fucose + NeuAcalpha(2,3) Galbeta(1,4) GlcNAcbeta(1,6)	GDP + NeuAcalpha(2,3)Galbeta(1,4) (Fucalpa(1,3)) GlcNAcbeta(1,6)		<u>Homo sapiens</u>	24.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA.	<u>637647</u>	-

(Galbeta(1,3)) GalNAcalpha-OMe	(Galbeta(1,3)) GalNAcalpha-OMe				12.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB		
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta-O-Bn	GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpa(1,3))GlcNAcbeta-O-Bn		<u>Homo sapiens</u>		6.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 7.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB	<u>637647</u>	-
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl	GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpa(1,3))GlcNAcbetaOallyl		<u>Homo sapiens</u>		380% of the activity with Galbeta(1,4)GlcNAc	<u>637634</u>	-
More	?		<u>Homo sapiens</u>		11 nonidentical amino acids, found within a hypervariable peptide segment positioned at the NH2 terminus determines whether or not a alpha(1,3)-fucosyltransferase can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties	<u>637640</u>	-
More	?		<u>Homo sapiens</u>		activity with type 2 substrates is 1% or less than the activity with type 1 substrates	<u>637642</u>	-
More	?		<u>Homo sapiens</u>		high substrate affinity for clustered units of 3-sialyl Galbeta(1,3)GlcNAcbeta in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galbeta1,4GlcNAcbeta-unit, in addition of alpha(1,2)-L-fucosylating activity	<u>637647</u>	-
More	?		<u>Homo sapiens</u>		no activity with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc, Fuc-alpha-1,2Gal-beta-1,4Glc, and NeuAc-alpha-2,3-Gal-beta-1,4GlcNAc	<u>661277</u>	-
More	?		<u>Homo sapiens</u>		the enzyme transfers fucose to the O-4-position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides and glycoproteins containing the type I Galbeta(1,3)GlcNAc motif	<u>637648</u>	-

More	?		<u>Macaca mulatta</u>	activity with type 2 substrates is 1% or less than the activity with type 1 substrates	<u>637642</u>	-	-
pyridylamine-lacto-N-neotetraose + GDP-fucose	GDP + ?		<u>Homo sapiens</u>	-	<u>661803</u>	-	-
NATURAL SUBSTRATES	NATURAL PRODUCTS	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)
GDP-fucose + Gal-beta-1,4GlcNAc-beta-1-R	GDP + Gal-beta-1,4(fuc-alpha-1,3)GlcNAc-beta-1-R		<u>Homo sapiens</u>	-	<u>661341</u>	-	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		<u>Homo sapiens</u>	the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation	<u>637637</u>	-	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		<u>Helicobacter pylori</u>	inactivation of the enzyme eliminates expression of all Lewis antigens	<u>637638</u>	-	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		<u>Homo sapiens</u>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637651</u>	-	-
GDP-L-fucose	GDP + 1,3-		<u>Homo</u>	the enzyme	<u>637652</u>	-	-

<b>+ 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R</b>	<b>beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R</b>		<b>sapiens</b>	may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme		
<b>GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R</b>	<b>GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R</b>		<b>Homo sapiens</b>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<b>637653</b>	-
<b>GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R</b>	<b>GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R</b>		<b>Homo sapiens</b>	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination.	<b>637654</b>	-

GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		Homo sapiens	Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637655</u>	-	-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		Homo sapiens	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637656</u>	-	+
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-		Homo sapiens	the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the	<u>637657</u>	-	-

R

expression of  
VIM-2, Lewis A,  
Lewis B, sialyl  
Lewis X and  
Lewis X/SSEA-  
1 antigens. May  
be involved in  
blood group  
Lewis  
determination.  
Lewis-positive  
individuals have  
an active  
enzyme while  
Lewis-negative  
individuals have  
an inactive  
enzyme

GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R

GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R



Homo sapiens

the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme

637658

-

-

GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R

GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R





Homo sapiens

the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have

637659

-

-

GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		<u>Homo sapiens</u>	an inactive enzyme the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme	<u>637660</u>	-	.
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R	GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R		<u>Pan troglodytes</u>	the enzyme may catalyze alpha-1,3 and alpha-1,4 glycosidic linkages involved in expression of sialyl Lewis X and Lewis X/SSEA-1 antigens. It may be involved in blood group Lewis determination	<u>637649</u>	-	.

## COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field





METALS and IONS	ORGANISM	COMMENTARY	LITERATURE
Ba2+	<u>Homo sapiens</u>	stimulates	<u>637635</u>
Ca2+	<u>Homo sapiens</u>	can replace Mn2+ for activation, optimum concentration is 10-15 mM	<u>660797</u>
Ca2+	<u>Homo sapiens</u>	leads to 2.1fold activation of SFT3	<u>661313</u>
Ca2+	<u>Homo sapiens</u>	stimulates	<u>637635</u>
Cd2+	<u>Homo sapiens</u>	stimulates	<u>637635</u>
Co2+	<u>Homo</u>	leads to 2.8fold activation of SFT3	<u>661313</u>









	<u>sapiens</u>		
Co2+	<u>Homo sapiens</u>	stimulates	<a href="#">637635</a>
Cu2+	<u>Homo sapiens</u>	no significant activity is detected	<a href="#">661313</a>
Mg2+	<u>Homo sapiens</u>	can replace Mn2+ for activation, optimum concentration is 10-15 mM	<a href="#">660797</a>
Mg2+	<u>Homo sapiens</u>	leads to 2.5fold activation of SFT3	<a href="#">661313</a>
Mg2+	<u>Homo sapiens</u>	stimulates, 20 mM required for maximal activation	<a href="#">637635</a>
Mg2+	<u>Silene alba</u>	required for activity	<a href="#">661845</a>
Mn2+	<u>Homo sapiens</u>	-	<a href="#">637636</a>
Mn2+	<u>Homo sapiens</u>	binds the enzyme and increases affinity for the acceptor. One possible functional role of manganese in catalysis can be as an electrophilic catalyst, co-ordinating the negative charges of the phosphate groups of the GDP-Fuc donor and promoting Fuc transfer. A low pH values such role would be played by the proton. Mn2+ leads to 2.7fold activation of SFT3	<a href="#">661313</a>
Mn2+	<u>Homo sapiens</u>	Fuc-T V is Mn2+ dependent	<a href="#">661341</a>
Mn2+	<u>Homo sapiens</u>	required for activation in vitro, optimum concentration is 10-15 mM	<a href="#">660797</a>
Mn2+	<u>Homo sapiens</u>	stimulates, activation is maximal at 5 mM	<a href="#">637635</a>
Mn2+	<u>Silene alba</u>	required for activity	<a href="#">661845</a>
Mn2+	<u>Vaccinium myrtillus</u>	activation above pH 8.0	<a href="#">637636</a>
More	<u>Homo sapiens</u>	Cu2+ inactivates the enzyme	<a href="#">660797</a>
More	<u>Homo sapiens</u>	the enzyme retains approximately 35% of its maximal activity in the absence of metal ions	<a href="#">661313</a>
Ni2+	<u>Homo sapiens</u>	stimulates	<a href="#">637635</a>
Zn2+	<u>Homo sapiens</u>	can replace Mn2+ for activation, but shows only half the maximal activity, optimum concentration is 10-15 mM	<a href="#">660797</a>
Zn2+	<u>Homo sapiens</u>	leads to 80% inhibition of STF3	<a href="#">661313</a>
Zn2+	<u>Homo sapiens</u>	stimulates	<a href="#">637635</a>

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
(-)-epigallocatechin-3-gallate	<u>Homo sapiens</u>	time-dependent, irreversible	<a href="#">660797</a>	● 2D-image
2'-Fucosyllactose	<u>Homo sapiens</u>	-	<a href="#">637634</a>	● 2D-image
2,3-Dihydroxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● 2D-image
2,4,6-Trinitrobenzenesulfonate	<u>Silene alba</u>	5 mM, activity is decreased to 82%; 5 mM, activity is decreased to 86%	<a href="#">661845</a>	● 2D-image
2,4-dihydroxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● 2D-image
2,5-dihydroxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● 2D-

	<u>sapiens</u>			image
3,4,5-Trihydroxybenzoic acid	<u>Homo sapiens</u>	gallic acid, time-dependent, irreversible	<a href="#">660797</a>	● <u>2D-image</u>
3,4,5-trimethoxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	-
3,4-Dihydroxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● <u>2D-image</u>
3,4-dimethoxybenzoic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● <u>2D-image</u>
3,5-dimethoxy 4-hydroxybenzoic acid	<u>Homo sapiens</u>	syringic acid	<a href="#">660797</a>	-
C-fucosyl analogon of GDP-fucose	<u>Homo sapiens</u>	-	<a href="#">661341</a>	-
carba-fucosyl analogon of GDP-fucose	<u>Homo sapiens</u>	-	<a href="#">661341</a>	-
Co2+	<u>Vaccinium myrtillus</u>	20 mM, 98% inhibition	<a href="#">637636</a>	● <u>2D-image</u>
Cu2+	<u>Vaccinium myrtillus</u>	20 mM, complete inhibition	<a href="#">637636</a>	● <u>2D-image</u>
Diethylpyrocarbonate	<u>Silene alba</u>	0.5 mM, activity is decreased to 11%; 0.5 mM, activity is decreased to 13%	<a href="#">661845</a>	● <u>2D-image</u>
Ellagic acid	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● <u>2D-image</u>
Ethylenediaminetetraacetic acid	<u>Silene alba</u>	-	<a href="#">661845</a>	● <u>2D-image</u>
Galbeta(1,3)GalNAc	<u>Homo sapiens</u>	-	<a href="#">637634</a>	● <u>2D-image</u>
Galbeta(1,4)(3-deoxy)GlcNAcbetaOallyl	<u>Homo sapiens</u>	IC50: 710 mM	<a href="#">637634</a>	● <u>2D-image</u>
Galbeta(1,4)deoxynojirimycin	<u>Homo sapiens</u>	IC50: 8 mM	<a href="#">637634</a>	● <u>2D-image</u>
GDP	<u>Homo sapiens</u>	0.05 mM	<a href="#">637634</a>	● <u>2D-image</u>
GDP	<u>Homo sapiens</u>	competitive with respect to GDP-fucose	<a href="#">637635</a>	● <u>2D-image</u>
GDP-Man	<u>Homo sapiens</u>	IC50: 2 mM	<a href="#">637634</a>	● <u>2D-image</u>
GMP	<u>Homo sapiens</u>	competitive with respect to GDP-fucose	<a href="#">637635</a>	● <u>2D-image</u>
lactitol	<u>Homo sapiens</u>	competitive with respect to lactose	<a href="#">637635</a>	-
lacto-N-fucopentaitol I	<u>Homo sapiens</u>	-	<a href="#">637635</a>	● <u>2D-image</u>
methyl gallate	<u>Homo sapiens</u>	-	<a href="#">660797</a>	● <u>2D-image</u>
Mn2+	<u>Vaccinium myrtillus</u>	20 mM, 40% inhibition below pH 8.0	<a href="#">637636</a>	● <u>2D-image</u>
More	<u>Silene alba</u>	the <u>Silene alba</u> alpha-4-FucT is insensitive to N-ethylmaleimide treatment (5 mM), in contrast to human FUT3	<a href="#">661845</a>	-
N-Bromosuccinimide	<u>Silene alba</u>	0.5 mM, activity is decreased to 8%; 0.5 mM, activity is decreased to 9%	<a href="#">661845</a>	● <u>2D-image</u>
NEM	<u>Homo</u>	-	<a href="#">637647</a>	● <u>2D-</u>

NEM	<del>sapiens</del> <u>Homo sapiens</u>	3 mM, 59°C	<u>637635</u>	 <del>image</del> <u>2D-image</u>
propyl gallate	<del>Homo sapiens</del>	-	<u>660797</u>	 <del>image</del> <u>2D-image</u>
unsaturated carba-fucosyl analogon of GDP-fucose	<del>Homo sapiens</del>	-	<u>661341</u>	-
Zn2+	Silene alba	-	<u>661845</u>	 <del>image</del> <u>2D-image</u>
Zn2+	<u>Yaccinium myrtillus</u>	20 mM, complete inhibition	<u>637636</u>	 <del>image</del> <u>2D-image</u>

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Phenylglyoxal	Silene alba	5 mM, FucT showed enhanced activity (114%); 5 mM, FucT shows enhanced activity (118%)	<u>661845</u>	 <del>image</del> <u>2D-image</u>

KM VALUE [mM]	KM VALUE [mM] Maximum	SUBSTRATE	ORGANISM	COMMENTARY	LITERATURE	IMAGE
11	-	2'-Fucosyllactose	<del>Homo sapiens</del>	-	<u>637635</u>	 <del>image</del> <u>2D-image</u>
0.16	-	2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	 <del>image</del> <u>2D-image</u>
0.4	-	2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn	<del>Homo sapiens</del>	enzyme form FTA	<u>637647</u>	 <del>image</del> <u>2D-image</u>
0.047	-	3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	 <del>image</del> <u>2D-image</u>
0.1	-	3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al	<del>Homo sapiens</del>	enzyme form FTA	<u>637647</u>	 <del>image</del> <u>2D-image</u>
0.045	-	ancrod	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	-
0.167	-	asialo ancrod	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	-
0.63	-	fetuin triantennary asialoglycopeptide	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	-
1.43	-	fetuin triantennary glycopeptide	<del>Homo sapiens</del>	enzyme form FTB	<u>637647</u>	-
0.2	-	Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<del>Homo sapiens</del>	wildtype	<u>661839</u>	-
0.3	-	Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<del>Homo sapiens</del>	mutant W111F; mutant W111Y	<u>661839</u>	-
2.5	-	Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<del>Homo sapiens</del>	mutant W111A	<u>661839</u>	-
0.1	-	Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	<del>Homo sapiens</del>	mutant W124R	<u>661839</u>	-
1.1	-	Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	<del>Homo sapiens</del>	wildtype	<u>661839</u>	-
1.3	-	Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	<del>Homo sapiens</del>	mutant W124Y	<u>661839</u>	-
0.1	-	Fucalpa(1,2)Galbeta(1,3)GlcNAc	<del>Homo sapiens</del>	-	<u>637645</u>	-
0.2	-	Fucalpa(1,2)Galbeta	<del>Homo sapiens</del>	wild-type enzyme	<u>637646</u>	-

		(1,3)GlcNAc	<u>sapiens</u>				
0.4	-	Fucalpha(1,2)Galbeta (1,3)GlcNAc	<u>Homo sapiens</u>	mutant enzyme D112E	<u>637646</u>	-	
2	-	Fucalpha(1,2)Galbeta (1,3)GlcNAc	<u>Homo sapiens</u>	mutant enzyme W111R/D112E	<u>637646</u>	-	
3.8	-	Fucalpha(1,2)Galbeta (1,3)GlcNAc	<u>Homo sapiens</u>	fucosyltransferase III mutant enzyme D336A	<u>637645</u>	-	
0.8	-	Fucalpha(1,2)Galbeta (1,3)GlcNAcbeta(1,3) Galbeta(1,4)Glc	<u>Homo sapiens</u>	-	<u>637634</u>	-	
1.52	-	Fucalpha(1,2)Galbeta (1,4)Glc	<u>Homo sapiens</u>	enzyme form FTB	<u>637647</u>	-	
0.5	-	Fucalpha(1,2)Galbeta (1,4)GlcNAc	<u>Homo sapiens</u>	mutant enzyme W111R/D112E	<u>637646</u>	-	
0.7	-	Fucalpha(1,2)Galbeta (1,4)GlcNAc	<u>Homo sapiens</u>	mutant enzyme W111R	<u>637646</u>	-	
8.4	-	Gal-beta-1,3-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	strain UA948	<u>662137</u>	-	
9.7	-	Gal-beta-1,3-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT UA948(1-360) 11639(360-478)	<u>662137</u>	-	
20.8	-	Gal-beta-1,3-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT 11639 (347CNDAHYSALH)	<u>662137</u>	-	
22.7	-	Gal-beta-1,3-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT UA948 (345DNPFIFC)	<u>662137</u>	-	
0.7	-	Gal-beta-1,3GlcNAcO (CH2)3NHCO(CH2)5NH- biotin	<u>Homo sapiens</u>	at pH 7.0 and presence of Mn2+	<u>661313</u>	-	
0.9	-	Gal-beta-1,3GlcNAcO (CH2)3NHCO(CH2)5NH- biotin	<u>Homo sapiens</u>	at pH 4.7 and absence of Mn2+	<u>661313</u>	-	
1.5	-	Gal-beta-1,3GlcNAcO (CH2)3NHCO(CH2)5NH- biotin	<u>Homo sapiens</u>	at pH 4.7 and presence of Mn2+	<u>661313</u>	-	
3.3	-	Gal-beta-1,3GlcNAcO (CH2)3NHCO(CH2)5NH- biotin	<u>Homo sapiens</u>	at pH 7.0 and absence of Mn2+	<u>661313</u>	-	
0.17	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT UA948 (345DNPFIFC)	<u>662137</u>	-	
0.31	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	wild type, strain NCTC116639	<u>662137</u>	-	
0.7	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT 11639(1-359) UA948(361-462)	<u>662137</u>	-	
1.2	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	strain UA948	<u>662137</u>	-	
1.3	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT UA948(1-360) 11639(360-478)	<u>662137</u>	-	
2.2	-	Gal-beta-1,4-GlcNAc-O- (CH2)8CO2CH3	<u>Helicobacter pylori</u>	chimeric FucT 11639 (347CNDAHYSALH)	<u>662137</u>	-	
0.6	-	Galbeta(1,3)GlcNAc	<u>Homo sapiens</u>	-	<u>637634</u>	-	● 2D- image
1.9	-	Galbeta(1,3)GlcNAc	<u>Homo sapiens</u>	-	<u>637635</u>	-	● 2D- image
12.7	-	Galbeta(1,3)GlcNAc	<u>Homo sapiens</u>	-	<u>637640</u>	-	● 2D- image

0.76	-	Galbeta(1,3)GlcNAc-(CH <sub>2</sub> ) <sub>3</sub> -NHCO-(CH <sub>2</sub> ) <sub>5</sub> -NH-biotin	<u>Homo sapiens</u>	enzyme expressed n Sf9 cells	<u>637643</u>	-
0.87	-	Galbeta(1,3)GlcNAc-(CH <sub>2</sub> ) <sub>3</sub> -NHCO-(CH <sub>2</sub> ) <sub>5</sub> -NH-biotin	<u>Homo sapiens</u>	enzyme expressed n Trichoplusia ni	<u>637643</u>	-
2.4	-	Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc	<u>Homo sapiens</u>	-	<u>637635</u>	● 2D-image
0.012	-	Galbeta(1,4)(5-thioGlc)	<u>Homo sapiens</u>	-	<u>637634</u>	● 2D-image
0.5	-	Galbeta(1,4)Glc	<u>Homo sapiens</u>	-	<u>637634</u>	● 2D-image
0.035	-	Galbeta(1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637634</u>	● 2D-image
1.6	-	Galbeta(1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637635</u>	● 2D-image
8.1	-	Galbeta(1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637640</u>	● 2D-image
0.4	-	Galbeta(1,4)GlcNAcbeta(1,2)Man	<u>Homo sapiens</u>	-	<u>637634</u>	-
3.8	-	Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc	<u>Homo sapiens</u>	-	<u>637635</u>	● 2D-image
0.016	-	Galbeta(1,4)GlcNAcbetaOallyl	<u>Homo sapiens</u>	-	<u>637634</u>	● 2D-image
0.034	-	Galbeta(1,4)Glucal	<u>Homo sapiens</u>	-	<u>637634</u>	● 2D-image
12	-	Galbeta(1,6)Galbeta(1,4)Glc	<u>Homo sapiens</u>	-	<u>637635</u>	-
0.016	-	GDP	<u>Homo sapiens</u>	-	<u>637635</u>	● 2D-image
0.1145	-	GDP-D-fucose	<u>Homo sapiens</u>	mutant enzyme D336A	<u>637645</u>	● 2D-image
0.03	-	GDP-fucose	<u>Homo sapiens</u>	mutant W124R, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.034	-	GDP-fucose	<u>Homo sapiens</u>	mutant W111Y, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.035	-	GDP-fucose	<u>Homo sapiens</u>	mutant W124Y, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin; wildtype, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.0357	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,3-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , strain UA948	<u>662137</u>	● 2D-image
0.037	-	GDP-fucose	<u>Homo sapiens</u>	mutant W111F, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.038	-	GDP-fucose	<u>Homo sapiens</u>	wildtype, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.046	-	GDP-fucose	<u>Homo sapiens</u>	mutant W111A, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin	<u>661839</u>	● 2D-image
0.048	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,4beta-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , wild type, strain NCTC116639	<u>662137</u>	● 2D-image
0.0481	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,4-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT UA948(345DNPFIFC)	<u>662137</u>	● 2D-image

0.0504	-	GDP-fucose	<u>Homo sapiens</u>	-	<u>661341</u>	● <u>2D-image</u>
0.0546	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,3-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT 11639(347CNDAHYSALH)	<u>662137</u>	● <u>2D-image</u>
0.0683	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,4-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , strain UA948	<u>662137</u>	● <u>2D-image</u>
0.153	-	GDP-fucose	<u>Helicobacter pylori</u>	with beta-Gal1,4-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT 11639(1-359)UA948(361-462)	<u>662137</u>	● <u>2D-image</u>
0.188	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,3-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT UA948(1-360)11639(360-478)	<u>662137</u>	● <u>2D-image</u>
0.213	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,3-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT UA948(345DNPFIFC)	<u>662137</u>	● <u>2D-image</u>
0.236	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,4-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT UA948(1-360)11639(360-478)	<u>662137</u>	● <u>2D-image</u>
0.244	-	GDP-fucose	<u>Helicobacter pylori</u>	with Gal-beta-1,4-GlcNAc-O-(CH <sub>2</sub> ) <sub>8</sub> CO <sub>2</sub> CH <sub>3</sub> , chimeric FucT 11639(347CNDAHYSALH)	<u>662137</u>	● <u>2D-image</u>
0.005	-	GDP-L-fucose	<u>Homo sapiens</u>	reaction with Galbeta(1,4)GlcNAc	<u>637635</u>	● <u>2D-image</u>
0.0105	-	GDP-L-fucose	<u>Homo sapiens</u>	reaction with Galbeta(1,3)GlcNAc	<u>637635</u>	● <u>2D-image</u>
0.0131	-	GDP-L-fucose	<u>Homo sapiens</u>	reaction with lactose	<u>637635</u>	● <u>2D-image</u>
0.03	-	GDP-L-fucose	<u>Homo sapiens</u>	mutant enzyme W111R	<u>637646</u>	● <u>2D-image</u>
0.032	-	GDP-L-fucose	<u>Homo sapiens</u>	mutant enzyme W111R/D112E	<u>637646</u>	● <u>2D-image</u>
0.033	-	GDP-L-fucose	<u>Homo sapiens</u>	mutant enzyme D112E	<u>637646</u>	● <u>2D-image</u>
0.0336	-	GDP-L-fucose	<u>Homo sapiens</u>	fucosyltransferase III	<u>637645</u>	● <u>2D-image</u>
0.035	-	GDP-L-fucose	<u>Homo sapiens</u>	wild-type enzyme	<u>637646</u>	● <u>2D-image</u>
0.06	-	GMP	<u>Homo sapiens</u>	-	<u>637635</u>	● <u>2D-image</u>
0.67	-	NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn	<u>Homo sapiens</u>	enzyme form FTB	<u>637647</u>	● <u>2D-image</u>
2.5	-	NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn	<u>Homo sapiens</u>	enzyme form FTA	<u>637647</u>	● <u>2D-image</u>
0.1	-	NeuAcalpha(2,3)Galbeta(1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637634</u>	● <u>2D-image</u>
0.28	-	NeuAcalpha(2,3)Galbeta(1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637634</u>	● <u>2D-image</u>
0.77	-	NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe	<u>Homo sapiens</u>	enzyme form FTB	<u>637647</u>	● <u>2D-image</u>
3.3	-	NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))	<u>Homo sapiens</u>	enzyme form FTB	<u>637647</u>	● <u>2D-image</u>

GalNAcalpha-OMe						
0.064	-	NeuAcalpha(2,3)Galbeta (1,4)Glucal	<u>Homo sapiens</u>	-	<u>637634</u>	● <u>2D-image</u>
0.07	-	NeuAcalpha(2,6)Galbeta (1,4)GlcNAc	<u>Homo sapiens</u>	-	<u>637634</u>	● <u>2D-image</u>
Ki VALUE [mM]	Ki VALUE [mM] Maximum	INHIBITOR	ORGANISM	COMMENTARY	LITERATURE	IMAGE
0.0007	-	(-)- epigallocatechin-3- gallate	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● <u>2D-image</u>
0.0022	-	(-)- epigallocatechin-3- gallate	<u>Homo sapiens</u>	60 min assay, no pre-incubation; overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, MnCl2 omitted in the overnight pre-incubation mixture	<u>660797</u>	● <u>2D-image</u>
7	-	2'-Fucosyllactose	<u>Homo sapiens</u>	-	<u>637635</u>	● <u>2D-image</u>
0.115	-	2,5- dihydroxybenzoic acid	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● <u>2D-image</u>
6e-05	-	3,4,5- Trihydroxybenzoic acid	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● <u>2D-image</u>
0.0054	-	3,4,5- Trihydroxybenzoic acid	<u>Homo sapiens</u>	overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, MnCl2 omitted in the overnight pre-incubation mixture	<u>660797</u>	● <u>2D-image</u>
0.008	-	3,4,5- Trihydroxybenzoic acid	<u>Homo sapiens</u>	60 min assay, no pre-incubation	<u>660797</u>	● <u>2D-image</u>
0.137	-	3,4- Dihydroxybenzoic acid	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● <u>2D-image</u>
0.889	-	C-fucosyl analogon of GDP- fucose	<u>Homo sapiens</u>	-	<u>661341</u>	-
0.0671	-	carba-fucosyl analogon of GDP- fucose	<u>Homo sapiens</u>	-	<u>661341</u>	-
0.0012	-	Ellagic acid	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● <u>2D-image</u>
17	-	lactitol	<u>Homo sapiens</u>	-	<u>637635</u>	-
0.6	-	lacto-N- fucopentaitol I	<u>Homo sapiens</u>	-	<u>637635</u>	● <u>2D-image</u>
0.008	-	methyl gallate	<u>Homo sapiens</u>	presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction	<u>660797</u>	● <u>2D-image</u>

additional information	-	More	<u>Homo sapiens</u>	with GDP-fucose 2,3-dihydroxybenzoic acid: above 0.200, presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 2,4-dihydroxybenzoic acid: above 0.200, presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,5-dimethoxy 4-hydroxybenzoic acid: above 0.200, presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,4-dimethoxybenzoic acid: above 0.200, presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,4,5-trimethoxybenzoic acid: above 0.200, presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	-
0.25	-	NEM	<u>Homo sapiens</u>	enzyme form FTA and FTB	<u>637647</u>	● 2D-image
0.045	-	propyl gallate	<u>Homo sapiens</u>	presence of MnCl <sub>2</sub> , overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose	<u>660797</u>	● 2D-image
0.0256	-	unsaturated carbafucosyl analogon of GDP-fucose	<u>Homo sapiens</u>	-	<u>661341</u>	-
pi VALUE	pi VALUE MAXIMUM	ORGANISM	COMMENTARY		LITERATURE	
8.9	-	Silene alba	membrane enzyme, isoelectric gel electrophoresis, chromatofocusing		<u>661845</u>	
8.8	-	Silene alba	soluble form, isoelectric gel electrophoresis, chromatofocusing		<u>661845</u>	
additional information	-	Silene alba	above 10.0, membrane enzyme, isoelectric gel electrophoresis, chromatofocussing		<u>661845</u>	
TURNOVER NUMBER[1/s]	TURNOVER NUMBER MAXIMUM[1/s]	SUBSTRATE	ORGANISM	COMMENTARY	LITERATURE	IMAGE
8.02	-	Fucalpha(1,2)Galbeta(1,3)GlcNAc	<u>Homo sapiens</u>	fucosyltransferase III	<u>637645</u>	-
3.02	-	Fucalpha(1,2)Galbeta(1,3)GlcNAc	<u>Homo sapiens</u>	fucosyltransferase III mutant enzyme D336A	<u>637645</u>	-
0.4	-	Galbeta(1,3)GlcNAc-(CH <sub>2</sub> ) <sub>3</sub> -NHCO-(CH <sub>2</sub> ) <sub>5</sub> -NH-biotin	<u>Homo sapiens</u>	enzyme expressed in Trichoplusia ni	<u>637643</u>	-
0.3	-	Gal-beta-1,3GlcNAcO(CH <sub>2</sub> ) <sub>3</sub> NHCO(CH <sub>2</sub> ) <sub>5</sub> NH-biotin	<u>Homo sapiens</u>	at pH 4.7 and absence of Mn <sup>2+</sup>	<u>661313</u>	-



0.2	-	Gal-beta-1,3GlcNAcO(CH <sub>2</sub> )3NHCO(CH <sub>2</sub> )5NH-biotin	<u>Homo sapiens</u>	at pH 4.7 and presence of Mn <sup>2+</sup> ; at pH 7.0 and presence of Mn <sup>2+</sup>	<u>661313</u>	-
0.1	-	Gal-beta-1,3GlcNAcO(CH <sub>2</sub> )3NHCO(CH <sub>2</sub> )5NH-biotin	<u>Homo sapiens</u>	at pH 7.0 and absence of Mn <sup>2+</sup>	<u>661313</u>	-
0.009	-	Galbeta(1,3)GlcNAc-(CH <sub>2</sub> )3-NHCO-(CH <sub>2</sub> )5-NH-biotin	<u>Homo sapiens</u>	enzyme expressed in Sf9 cells	<u>637643</u>	-

SPECIFIC ACTIVITY [μmol/min/mg]	SPECIFIC ACTIVITY MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
567	-	<u>Homo sapiens</u>	enzyme expressed in Sf9 cells	<u>637643</u>
72	-	<u>Homo sapiens</u>	enzyme expressed in Trichoplusia ni	<u>637643</u>
2.05	-	<u>Homo sapiens</u>	reaction with 2'-fucosyllactose	<u>637635</u>
1.13	-	<u>Homo sapiens</u>	reaction with lacto-N-fucopentaose I	<u>637635</u>
0.061	-	<u>Homo sapiens</u>	-	<u>637647</u>
0.0238	-	<u>Helicobacter pylori</u>	alpha-1,3 activity, alpha-1,4 activity is one third of the alpha 1,3-activity	<u>662137</u>
0.0163	-	<u>Helicobacter pylori</u>	alpha 1,3 activity, wild type, strain NCTC116639	<u>662137</u>
0.000312	-	<u>Silene alba</u>	type 1 acceptor (Gal-beta-1,3GlcNAc-beta-O-(CH <sub>2</sub> )7CH <sub>3</sub> )	<u>661845</u>
0.000265	-	<u>Silene alba</u>	H-type 1 acceptor (Fuc-alpha-1,2Gal-beta-1,3GlcNAc-O-C <sub>6</sub> H <sub>5</sub> )	<u>661845</u>
6.7e-05	-	<u>Silene alba</u>	stamen	<u>661845</u>
5.2e-05	-	<u>Silene alba</u>	type 1 acceptor (Gal-beta-1,3GlcNAc-beta-O-(CH <sub>2</sub> )7CH <sub>3</sub> )	<u>661845</u>
5e-05	-	<u>Silene alba</u>	seedling	<u>661845</u>
4.5e-05	-	<u>Silene alba</u>	H-type 1 acceptor (Fuc-alpha-1,2Gal-beta-1,3GlcNAc-O-C <sub>6</sub> H <sub>5</sub> )	<u>661845</u>
3.9e-05	-	<u>Silene alba</u>	young roots	<u>661845</u>
2.6e-05	-	<u>Silene alba</u>	young leaves	<u>661845</u>
1.5e-05	-	<u>Silene alba</u>	root; pistill	<u>661845</u>
2e-06	-	<u>Silene alba</u>	shoot; old roots; petal	<u>661845</u>
1e-06	-	<u>Silene alba</u>	old leaves; sepal	<u>661845</u>
additional information	-	<u>Homo sapiens</u>	-	<u>637637</u>
additional information	-	<u>Silene alba</u>	below 0.0000001, H-type 2 acceptor (Fuc-alpha-1,2Gal-beta-1,4GlcNAc-O-C <sub>6</sub> H <sub>5</sub> ); below 0.0000001, type 2 acceptor (Gal-beta-1,4GlcNAc-beta-O-(CH <sub>2</sub> )7CH <sub>3</sub> )	<u>661845</u>

pH OPTIMUM	pH MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
------------	------------	----------	------------	------------

8	-	<u>Silene alba</u>	-	<u>661845</u>
7	-	<u>Homo sapiens</u>	in the presence of Mn2+	<u>661313</u>
7	-	<u>Vaccinium myrtillus</u>	both in the presence and in absence of Mn2+	<u>637636</u>
7	7.8	<u>Homo sapiens</u>	-	<u>637635</u>
4.5	-	<u>Homo sapiens</u>	in the absence of Mn2+	<u>661313</u>

pH RANGE	pH RANGE MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
6.2	8.5	<u>Homo sapiens</u>	pH 6.2: about 70% of maximal activity, pH 8.5: about 90% of maximal activity	<u>637635</u>
6	8	<u>Homo sapiens</u>	in the presence of Mn2+	<u>661313</u>

TEMPERATURE OPTIMUM	TEMPERATURE OPTIMUM MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
45	-	<u>Silene alba</u>	-	<u>661845</u>
40	-	<u>Vaccinium myrtillus</u>	-	<u>637636</u>

TEMPERATURE RANGE	TEMPERATURE MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
25	50	<u>Silene alba</u>	-	<u>661845</u>
25	50	<u>Vaccinium myrtillus</u>	25°C: about 50% of maximal activity, 50°C: about 40% of maximal activity	<u>637636</u>

SOURCE TISSUE	ORGANISM	COMMENTARY	LITERATURE	SOURCE
brain	<u>Bos taurus</u>	-	<u>637650</u>	<u>BRENDA</u>
cell suspension culture	<u>Vaccinium myrtillus</u>	-	<u>637636</u>	<u>BRENDA</u>
colon	<u>Rattus norvegicus</u>	-	<u>489362</u>	<u>BRENDA</u>
epithelial cell	<u>Homo sapiens</u>	cystic fibrosis airway epithelial cell	<u>661277</u>	<u>BRENDA</u>
HEK-293 cell	<u>Homo sapiens</u>	-	<u>660797</u>	<u>BRENDA</u>
kidney	<u>Bos taurus</u>	-	<u>637650</u>	<u>BRENDA</u>
leaf	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
liver	<u>Bos taurus</u>	-	<u>637650</u>	<u>BRENDA</u>
liver	<u>Homo sapiens</u>	-	<u>637652</u>	<u>BRENDA</u>
lung	<u>Bos taurus</u>	-	<u>637650</u>	<u>BRENDA</u>
lung cancer cell	<u>Homo sapiens</u>	-	<u>637647</u>	<u>BRENDA</u>
milk	<u>Homo sapiens</u>	-	<u>637634</u>	<u>BRENDA</u>
petal	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
pistil	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
root	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
sepal	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
shoot	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>
stamen	<u>Silene alba</u>	-	<u>661845</u>	<u>BRENDA</u>

LOCALIZATION	ORGANISM	COMMENTARY	GeneOntology No.	LITERATURE	SOURCE
					<u>BRENDA</u>

cell surface	<u>Homo sapiens</u>	fusion proteins PIR1-HA-FUT6 and PIR2-FLAG-FUT6	-	<a href="#">661803</a>	
Golgi apparatus	<u>Homo sapiens</u>	-	-	<a href="#">637637</a>	<b>BRENDA</b>
Golgi cis-face	<u>Mesocricetus auratus</u>	FT3dc mutant	-	<a href="#">661236</a>	<b>BRENDA</b>
Golgi membrane	<u>Silene alba</u>	-	-	<a href="#">661845</a>	<b>BRENDA</b>
Golgi trans face	<u>Mesocricetus auratus</u>	FT3 wildtype	-	<a href="#">661236</a>	<b>BRENDA</b>
Golgi trans-face	<u>Homo sapiens</u>	Golgi type II membrane protein	-	<a href="#">637637</a>	<b>BRENDA</b>
membrane	<u>Bos taurus</u>	-	-	<a href="#">637650</a>	<b>BRENDA</b>
membrane	<u>Homo sapiens</u>	-	-	<a href="#">637637</a> , <a href="#">637651</a> , <a href="#">637652</a> , <a href="#">637653</a> , <a href="#">637654</a> , <a href="#">637655</a> , <a href="#">637656</a> , <a href="#">637657</a> , <a href="#">637658</a> , <a href="#">637659</a> , <a href="#">637660</a>	<b>BRENDA</b>
membrane	<u>Homo sapiens</u>	stable BHK-21 cell lines express the Golgi bound form and two secretory forms of the enzyme	-	<a href="#">637648</a>	<b>BRENDA</b>
membrane	<u>Pan troglodytes</u>	-	-	<a href="#">637649</a>	<b>BRENDA</b>
microsome	<u>Vaccinium myrtillus</u>	-	-	<a href="#">637636</a>	<b>BRENDA</b>
soluble	<u>Homo sapiens</u>	-	-	<a href="#">637637</a> , <a href="#">662484</a>	<b>BRENDA</b>
soluble	<u>Homo sapiens</u>	stable BHK-21 cell lines express the Golgi bound form and two secretory forms of the enzyme. 40% of the enzyme activity synthesized by cells transfected with the Golgi form of the enzyme are constitutively secreted into the medium	-	<a href="#">637648</a>	<b>BRENDA</b>
soluble	<u>Silene alba</u>	-	-	<a href="#">661845</a>	<b>BRENDA</b>

ACCESSION CODE	ENTRY NAME	ORGANISM	NO. OF AA	MOLECULAR WEIGHT[Da]	SOURCE	Sequence
<a href="#">Q8HYJ4 pBLAST</a>	FUT5_PONPY	<u>Pongo pygmaeus</u>	374	43035	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">P56433 pBLAST</a>	FUT5_PANTR	<u>Pan troglodytes</u>	374	43034	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">P51993 pBLAST</a>	FUT6_HUMAN	<u>Homo sapiens</u>	359	41860	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q8HYJ3 pBLAST</a>	FUT5_HYLLA	<u>Hylobates lar</u>	374	43091	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q8HYJ6 pBLAST</a>	FUT6_GORGO	<u>Gorilla gorilla gorilla</u>	359	41688	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q8HYJ7 pBLAST</a>	FUT5_GORGO	<u>Gorilla gorilla gorilla</u>	374	43122	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q8HYJ5 pBLAST</a>	FUT3_PONPY	<u>Pongo pygmaeus</u>	372	43008	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">P21217 pBLAST</a>	FUT3_HUMAN	<u>Homo sapiens</u>	361	42117	Swiss-Prot	<a href="#">Show Sequence</a>

<a href="#">Q19058</a> <a href="#">pBLAST</a>	FUT3_PANTR	<a href="#">Pan troglodytes</a>	372	43234	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q11126</a> <a href="#">pBLAST</a>	FUT3_BOVIN	<a href="#">Bos taurus</a>	365	42654	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q9GKU6</a> <a href="#">pBLAST</a>	FUT6_PONPY	<a href="#">Pongo pygmaeus</a>	359	41848	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q11126</a> <a href="#">pBLAST</a>	FUT5_HUMAN	<a href="#">Homo sapiens</a>	374	43008	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">P56434</a> <a href="#">pBLAST</a>	FUT6_PANTR	<a href="#">Pan troglodytes</a>	359	41893	Swiss-Prot	<a href="#">Show Sequence</a>
<a href="#">Q5TJK3</a> <a href="#">pBLAST</a>	Q5TJK3_PHYPA	<a href="#">Physcomitrella patens</a>	437	48951	TrEMBL	<a href="#">Show Sequence</a>
<a href="#">Q599J3</a> <a href="#">pBLAST</a>	Q599J3_9ROSI	<a href="#">Populus tremula</a> x <a href="#">Populus alba</a>	430	48213	TrEMBL	<a href="#">Show Sequence</a>

## PDB ORGANISM

No entries in this field

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
56000	-	<a href="#">Helicobacter pylori</a>	SDS-PAGE	<a href="#">662137</a>
54600	-	<a href="#">Helicobacter pylori</a>	SDS-PAGE	<a href="#">662137</a>
41800	-	<a href="#">Homo sapiens</a>	SDS-PAGE, immunoblot	<a href="#">661839</a>
additional information	-	<a href="#">Homo sapiens</a>	disulfide bonds in FucT III occur between Cys residues Cys81 and Cys338 and between Cys91 and Cys341 at the N and C termini of the catalytic domain, bringing these ends close together in space	<a href="#">637641</a>
additional information	-	<a href="#">Pan troglodytes</a>	there are two alleles, A and B. Allele A has Arg162 and Val304 allele B has Gly162 and Met304	<a href="#">637649</a>
additional information	-	<a href="#">Silene alba</a>	above 100 kDa for the membrane-anchored enzyme, selective ultra-filtration; between 50 and 100 kDa for the soluble enzyme, selective ultra-filtration	<a href="#">661845</a>

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
?	<a href="#">Homo sapiens</a>	-	<a href="#">637651</a>
?	<a href="#">Homo sapiens</a>	x * 40000-42000, SDS-PAGE	<a href="#">637648</a>
?	<a href="#">Homo sapiens</a>	x * 42117, calculation from nucleotide sequence	<a href="#">637660</a>
?	<a href="#">Homo sapiens</a>	x * 51000 + x * 53000, SDS-PAGE	<a href="#">637635</a>
?	<a href="#">Pan troglodytes</a>	x * 43233, calculation from nucleotide sequence	<a href="#">637649</a>
?	<a href="#">Rattus norvegicus</a>	x * 68780, SDS-PAGE	<a href="#">489362</a>
More	<a href="#">Homo sapiens</a>	the enzyme is present in an equilibrium of monomer/dimer in the trans-Golgi/trans-Golgi-network of transfected BHK cells	<a href="#">637637</a>

POSTTRANSLATIONAL MODIFICATION	ORGANISM	COMMENTARY	LITERATURE
Glycoprotein	<a href="#">Homo</a>	the two glycosylation sites from SFT3 are occupied by peptide-	<a href="#">637643</a>

	<u>sapiens</u>	N-glycanase F, whereas 50% of SFT3 secreted by Tn cells is resistant to deglycosylation by this enzyme	
Glycoprotein	<u>Homo sapiens</u>	the secretory variant of enzyme contains N-linked endo H sensitive carbohydrate chains at its two glycosylation sites	<u>637648</u>
More	<u>Homo sapiens</u>	the enzyme expressed in Tn cell line has a lower global charge, possibly due to post-translational modifications, such as phosphorylatopm or sulfation	<u>637643</u>

## Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

## pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE STABILITY	TEMPERATURE STABILITY MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
50	-	<u>Vaccinium myrtillus</u>	stable up to	<u>637636</u>
45	-	Silene alba	stable up to 45°C; the enzyme is stable up to 45°C	<u>661845</u>

## GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

## ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

## OXIDATION STABILITY ORGANISM LITERATURE

No entries in this field

STORAGE STABILITY	ORGANISM	LITERATURE
-20°C, 50% glycerol, protein concentration 0.03 mg/ml	<u>Homo sapiens</u>	<u>637635</u>

Purification/COMMENTARY	ORGANISM	LITERATURE
-	<u>Rattus norvegicus</u>	<u>489362</u>
-	Silene alba	<u>661845</u>
-	<u>Homo sapiens</u>	<u>637635, 637637, 637643, 660797</u>
anion exchange-chromatography on a CM-Sepharose column, followed by an affinity chromatography on a GDP Fractogel column	<u>Homo sapiens</u>	<u>661313</u>
secretory variant of enzyme	<u>Homo sapiens</u>	<u>637648</u>
two molecular forms: FTA and FTB	<u>Homo sapiens</u>	<u>637647</u>

Cloned/COMMENTARY	ORGANISM	LITERATURE
-	<u>Helicobacter pylori</u>	<u>637638</u>
-	<u>Pongo pygmaeus</u>	<u>661839</u>

-	<u>Hylobates lar</u>	<u>661839</u>
-	<u>Homo sapiens</u>	<u>661277, 661433, 661839</u>
-	<u>Gorilla gorilla</u>	<u>661839</u>
cloning of chimeric FucTs, expression in Escherichia coli HMS174DE3 cells	<u>Helicobacter pylori</u>	<u>662137</u>
construction of plasmids encoding soluble forms of the recombinant human FucT-III where the human IL-2 sequence is linked to Ala47 or Val-36 of the FucT-III and expression in stable transfected BHK-21 cell lines	<u>Homo sapiens</u>	<u>637648</u>
expression in BHK-21B cells	<u>Homo sapiens</u>	<u>637637</u>
expression in COS cells	<u>Homo sapiens</u>	<u>637644</u>
expression in HEK 293 cells	<u>Homo sapiens</u>	<u>660797</u>
expression in Saccharomyces cerevisiae, construction of fusion genes PIR1-HA-FUT6 and PIR2-FLAG-FUT6	<u>Homo sapiens</u>	<u>661803</u>
expression in Spodoptera frugiperda (Sf9) insect cells	<u>Homo sapiens</u>	<u>661313</u>
expression in Spodoptera frugiperda SF-9 cells, the secreted activity SFT3 increases until the 6th day of culture when it reaches the value 1.9 mU x 10 <sup>-6</sup> cells and 13.4 mg/l, whereas only 5% of activity is retained inside the cells	<u>Homo sapiens</u>	<u>662484</u>
expression of a secreted form of Fuc-TIII, SFT3, in two insect cell lines, Spodoptera frugiperda and Trichoplusia ni using the baculovirus expression system. The enzyme from the Tn cell line has a lower global charge, possibly due to post-translational modifications, such as phosphorylation or sulfation	<u>Homo sapiens</u>	<u>637643</u>

ENGINEERING	ORGANISM	COMMENTARY	LITERATURE
D112E	<u>Homo sapiens</u>	mutation decreases activity of the enzyme and does not interfere with H-type 1/H-type 2 acceptors	<u>637646</u>
D336A	<u>Homo sapiens</u>	fucosyltransferase III mutant enzyme shows reduced activity with a variety of acceptors, 40fold reduction in activity for Fucal $\alpha$ 1,2Gal $\beta$ 1,3)GlcNAc. 4fold reduction affinity for GDP-fucose. The single amino acid site Asp336 of FucT III and Ala349 of FucT V constitutes the only difference in the sequence of FucT III and V over the final 210 COOH-terminal amino acid residues, impacts the acceptor substrate profiles of FucT III and FucT V	<u>637645</u>
FT3dc	<u>Mesocricetus auratus</u>	mutant where the cytoplasmic domain (Asp-2 to Trp-13) is deleted	<u>661236</u>
R110H	<u>Homo sapiens</u>	less than 10% of the wild type $\alpha$ -1,3-activity and undetectable $\alpha$ -1,4-activity	<u>661839</u>
R110K	<u>Homo sapiens</u>	less than 10% of the wild type $\alpha$ -1,3-activity and undetectable $\alpha$ -1,4-activity	<u>661839</u>
R110N	<u>Homo sapiens</u>	less than 10% of the wild type $\alpha$ -1,3-activity and undetectable $\alpha$ -1,4-activity	<u>661839</u>
R110Q	<u>Homo sapiens</u>	less than 10% of the wild type $\alpha$ -1,3-activity and undetectable $\alpha$ -1,4-activity	<u>661839</u>
R110W	<u>Homo sapiens</u>	no $\alpha$ -1,3-activity or $\alpha$ -1,4-activity	<u>661839</u>
W111A	<u>Homo sapiens</u>	$\alpha$ -1,4-activity is decreased to 10-20% of the wild type activity	<u>661839</u>
W111F	<u>Homo sapiens</u>	$\alpha$ -1,4-activity is decreased to 42% of the wild type activity	<u>661839</u>
W111R	<u>Homo sapiens</u>	the mutation changes the specificity for fucose transfer from H-type 1 to H-type 2 acceptors	<u>637646</u>
W111Y	<u>Homo sapiens</u>	$\alpha$ -1,4-activity is decreased to 58% of the wild type activity	<u>661839</u>

W11R/D112E	<u>Homo sapiens</u>	the mutation changes the specificity for fucose transfer from H-type 1 to H-type 2 acceptors. Increased type 2 activity compared to mutant W111R	<a href="#">637646</a>
W124A	<u>Homo sapiens</u>	alpha-1,4-activity is decreased to 20% of the wild type activity	<a href="#">661839</a>
W124F	<u>Homo sapiens</u>	alpha-1,4-activity is decreased to 17% of the wild type activity	<a href="#">661839</a>
W124R	<u>Homo sapiens</u>	undetectable alpha-1,4-activity	<a href="#">661839</a>
W124V	<u>Homo sapiens</u>	undetectable alpha-1,4-activity	<a href="#">661839</a>
W124Y	<u>Homo sapiens</u>	alpha-1,4-activity is decreased to 52% of the wild type activity	<a href="#">661839</a>

## Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

APPLICATION	ORGANISM	COMMENTARY	LITERATURE
molecular biology	<u>Homo sapiens</u>	the stable system using the expression vector pIB/Vf-His-TOPO constitutes an advance for the large scale expression of glycosyltransferases and possibly other glycoproteins in insect cells	<a href="#">662484</a>
synthesis	<u>Homo sapiens</u>	by constructing yeast cells that display human FUT6 on the cell wall by fusion of FUT6 with the yeast cell wall proteins Pir1 and Pir2, the fucosylated oligosaccharides can be easily synthesized by the incubation of yeast cells with an appropriate donor and acceptor. It will thus be possible to prepare a large amount of immobilized FUT6 fused with Pir proteins in an inexpensive medium lacking the serum that is required for mammalian cell cultivation	<a href="#">661803</a>
synthesis	<u>Homo sapiens</u>	the soluble form of fucosyltransferase III secreted by stably transfected cells may be used for in vitro synthesis of the Lewis 1 determinant on carbohydrates and glycoproteins	<a href="#">637648</a>

## DISEASE TITLE OF PUBLICATION LINK TO PUBMED

No entries in this field

REF.	AUTHORS	TITLE	JOURNAL	VOL.	PAGES	YEAR	ORGANISM	LINK TO PUBMED	SOURCE
<a href="#">349717</a>	Leiter, H.; Mucha, J.; Staudacher, E.; Grimm, R.; Glossl, J.; Altmann, F.	Purification, cDNA cloning, and expression of GDP-L-Fuc:Asn-linked GlcNAc alpha1,3-fucosyltransferase from mung beans	J. Biol. Chem.	274	21830-21839	1999	:	● <a href="#">PubMed</a>	<b>FRENDA</b>
<a href="#">349726</a>	DeBose-Boyd, R.A.; Nyame, A.K.; Cummings, R.D.	Schistosoma mansoni: characterization of an alpha 1-3 fucosyltransferase in adult parasites	Exp. Parasitol.	82	1-10	1996	:	● <a href="#">PubMed</a>	<b>FRENDA</b>
<a href="#">489362</a>	Karaivanova, V.; Mookerjee, S.; Hunt, D.; Nagpurkar, A.	Characterization and purification of fucosyltransferases from the cytosol of rat colon	Int. J. Biochem. Cell Biol.	28	165-174	1996	Rattus norvegicus	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">637634</a>	Wong, C.-H.; Dumas, D.P.; Ichikawa, Y.; Koseki, K.; Danishefsky, S.J.; Weston, B.W.; Lowe, J.B.	Specificity, inhibition, and synthetic utility of a recombinant human alpha-1,3-fucosyltransferase	J. Am. Chem. Soc.	114	7321-7322	1992	Homo sapiens	-	<b>BRENDA</b>

<b>637635</b>	Prieels, J.-P.; Monnom, D.; Dolmans, M.; Beyer, T.A.; Hill, R.L.	Co-purification of the Lewis blood group N- acetylglucosaminide alpha 1 goes to 4 fucosyltransferase and an N- acetylglucosaminide alpha 1 goes to 3 fucosyltransferase from human milk	J. Biol. Chem.	256	10456- 10463	1981	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637636</b>	Palma, A.S.; Vila-Verde, C.; Pires, A.S.; Feverleiro, P.S.; Costa, J.	A novel plant alpha4- fucosyltransferase (Vaccinium myrtillus L.) synthesises the Lewis adhesion determinant	FEBS Lett.	499	235- 238	2001	Homo sapiens, Vaccinium myrtillus	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637637</b>	Sousa, V.L.; Costa, M.T.; Palma, A.S.; Enguita, F.; Costa, J.	Localization, purification and specificity of the full-length membrane-bound form of human recombinant alpha 1,3/4- fucosyltransferase from BHK-21B cells	Biochem. J.	357	803- 810	2001	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637638</b>	Raško, D.A.; Wang, G.; Palcic, M.M.; Taylor, D.E.	Cloning and characterization of the alpha(1,3/4) fucosyltransferase of Helicobacter pylori	J. Biol. Chem.	275	4988- 4994	2000	Helicobacter pylori	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637640</b>	Legault, D.J.; Kelly, R.J.; Natsuka, Y.; Lowe, J.B.	Human alpha (1,3/1,4)- fucosyltransferases discriminate between different oligosaccharide acceptor substrates through a discrete peptide fragment	J. Biol. Chem.	270	20987- 20996	1995	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637641</b>	Holmes, E.H.; Yen, T.-Y.; Thomas, S.; Joshi, R.; Nguyen, A.; Long, T.; Gallet, F.; Maftah, A.; Julien, R.; Macher, B.A.	Human alpha1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites	J. Biol. Chem.	275	24237- 24245	2000	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637642</b>	Dupuy, F.; Germot, A.; Marenda, M.; Oriol, R.; Blancher, A.; Julien, R.; Maftah, A.	alpha1,4- Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently	Mol. Biol. Evol.	19	815- 824	2002	Homo sapiens, Macaca mulatta	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637643</b>	Morais, V.A.; Serpa, J.; Palma, A.S.; Costa, T.;	Expression and characterization of recombinant human	Biochem. J.	353	719- 725	2001	Homo sapiens	● <a href="#">PubMed</a>	



	Maranga, L.; Costa, J.	alpha-3/4- fucosyltransferase III from <i>Spodoptera frugiperda</i> (Sf9) and <i>Trichoplusia ni</i> (Tn) cells using the baculovirus expression system							<b>BRENDA</b>
<b>637644</b>	Weston, B.W.; Nair, R.P.; Larsen, R.D.; Lowe, J.B.	Isolation of a novel human alpha (1,3) fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4) fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities	J. Biol. Chem.	267	4152- 4160	1992	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637645</b>	Vo, L.; Lee, S.; Marcinko, M.C.; Holmes, E.H.; Macher, B.A.	Human alpha1,3/4- fucosyltransferases II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties	J. Biol. Chem.	273	25250- 25255	1998	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637646</b>	Dupuy, F.; Petit, J.-M.; Mollicone, R.; Oriol, R.; Julien, R.; Maftah, A.	A single amino acid in the hypervariable stem domain of vertebrate alpha1,3/1,4- fucosyltransferases determines the type 1/type 2 transfer. Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagenesis	J. Biol. Chem.	274	12257- 12262	1999	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<b>637647</b>	Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Xia, J.; Piskorz, C.; Matta, K.L.	Human lung adenocarcinoma alpha1,3/4-L- fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel alpha1,2- L-fucosylating activity	Glycobiology 11	353- 363	2001	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>	
<b>637648</b>	Costa, J.; Grabenhorst, E.; Nimtz, M.; Conradt, H.S.	Stable expression of the Golgi form and secretory variants of human fucosyltransferase	J. Biol. Chem.	272	11613- 11621	1997	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>

		III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium						
<b>637649</b>	Costache, M.; Apoil, P.-A.; Cailleau, A.; Elmgren, A.; Larson, G.; Henry, S.; Blancher, A.; Iordachescu, D.; Oriol, R.; Mollicone, R.	Evolution of fucosyltransferase genes in vertebrates	J. Biol. Chem.	272	29721-29728	1997	Pan troglodytes	● PubMed BRENDA
<b>637650</b>	Oulmouden, A.; Wierinckx, A.; Petiti, J.-M.; Costache, M.; Palcic, M.M.; Mollicone, R.; Oriol, R.; Julien, R.	Molecular cloning and expression of a bovine alpha(1,3)-fucosyltransferase gene homologous to a putative ancestor gene of the human FUT3-FUT5-FUT6 cluster.	J. Biol. Chem.	272	8764-8773	1997	Bos taurus	● PubMed BRENDA
<b>637651</b>	Kukowska-Latallo, J.F.; Larsen, R.D.; Nair, R.P.; Lowe, J.B.	A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4) fucosyltransferase.	Genes Dev.	4	1288-1303	1990	Homo sapiens	● PubMed BRENDA
<b>637652</b>	Cameron, H.S.; Szczepaniak, D.; Weston, B.W.	Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms	J. Biol. Chem.	270	20112-20122	1995	Homo sapiens	● PubMed BRENDA
<b>637653</b>	Elmgren, A.; Rydberg, L.; Larson, G.	Genotypic heterogeneity among Lewis negative individuals	Biochem. Biophys. Res. Commun.	196	515-520	1993	Homo sapiens	● PubMed BRENDA
<b>637654</b>	Nishihara, S.; Yazawa, S.; Iwasaki, H.; Nakazato, M.; Kudo, T.; Ando, T.; Narimatsu, H.	alpha(1,3/1,4) fucosyltransferase (FucT-III) gene is inactivated by a single amino acid substitution in Lewis histo-blood type negative individuals	Biochem. Biophys. Res. Commun.	196	624-631	1993	Homo sapiens	● PubMed BRENDA
<b>637655</b>	Koda, Y.; Kimura, H.; Mekada, E.	Analysis of Lewis fucosyltransferase genes from the human gastric mucosa of Lewis-positive and -negative individuals.	Blood	82	2915-2919	1993	Homo sapiens	● PubMed BRENDA

<a href="#">637656</a>	Mollicone, R.; Reguigne, I.; Kelly, R.J.; Fletcher, A.; Watt, J.; Chatfield, S.; Aziz, A.; Cameron, H.S.; Weston, B.W.; Lowe, J.B.; Oriol, R.	Molecular basis for Lewis alpha(1,3/1,4)- fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees	J. Biol. Chem.	269	20987- 20994	1994	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">637657</a>	Nishihara, S.; Narimatsu, H.; Iwasaki, H.; Yazawa, S.; Akamatsu, S.; Ando, T.; Sena, T.; Narimatsu, I.	Molecular genetic analysis of the human Lewis histo- blood group system	J. Biol. Chem.	269	29271- 29278	1994	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">637658</a>	Elmgren, A.; Boerjeson, C.; Svensson, L.; Rydberg, L.; Larson, G.	DNA sequencing and screening for point mutations in the human Lewis 'FUT' gene enables molecular genotyping of the human Lewis blood group system	Vox Sang.	70	97-103	1996	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">637659</a>	Elmgren, A.; Mollicone, R.; Costache, M.; Boerjeson, C.; Oriol, R.; Harrington, J.; Larson, G.	Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha (1,3/1,4)- fucosyltransferase, Fuc-TIII.	J. Biol. Chem.	272	21994- 21998	1997	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">637660</a>	Pang, H.; Liu, Y.; Koda, Y.; Soejima, M.; Jia, J.; Schlaphoff, T.; du Toit, E.D.; Kimura, H.	Five novel missense mutations of the Lewis gene 'FUT3' in African 'Xhosa' and Caucasian populations in South Africa'	Hum. Genet.	102	675- 680	1998	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">646835</a>	Farkas, V.; Sulova, Z.; Stratilova, E.; Hanna, R.; MacIachlan, G.	Cleavage of xyloglucan by nasturtium seed xyloglucanase and transglycosylation to xyloglucan subunit oligosaccharides	Arch. Biochem. Biophys.	298	365- 370	1992	Pisum sativum	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">660797</a>	Niu, X.; Fan, X.; Sun, J.; Ting, P.; Narula, S.; Lundell, D.	Inhibition of fucosyltransferase VII by gallic acid and its derivatives	Arch. Biochem. Biophys.	425	51-57	2004	Homo sapiens	● <a href="#">PubMed</a>	<b>BRENDA</b>
<a href="#">661236</a>	Sousa, V.L.; Brito, C.; Costa, J.	Deletion of the cytoplasmic domain of human alpha3/4 fucosyltransferase III causes the shift of the enzyme to	Biochim. Biophys. Acta	1675	95-104	2004	Mesocricetus auratus	● <a href="#">PubMed</a>	<b>BRENDA</b>

		early Golgi compartments							
<b>661277</b>	Stoykova, L.I.; Liu, A.; Scanlin, T.F.; Glick, M.C.	alpha1,3 Fucosyltransferases in cystic fibrosis airway epithelial cells	Biochimie	85	363-367	2003	Homo sapiens	-	<b>BRENDA</b>
<b>661313</b>	Palma, A.S.; Morais, V.A.; Coelho, A.V.; Costa, J.	Effect of the manganese ion on human alpha3/4 fucosyltransferase III activity	BioMetals	17	35-43	2004	Homo sapiens	● PubMed	<b>BRENDA</b>
<b>661341</b>	Norris, A.J.; Whitelegge, J.P.; Strouse, M.J.; Faull, K.F.; Toyokuni, T.	Inhibition kinetics of carba- and C-fucosyl analogues of GDP-fucose against fucosyltransferase V: implication for the reaction mechanism	Bioorg. Med. Chem. Lett.	14	571-573	2004	Homo sapiens	● PubMed	<b>BRENDA</b>
<b>661433</b>	Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Locke, R.D.; Piskorz, C.F.; Matta, K.L.	The binding characteristics and utilization of Aleuria aurantia, Lens culinaris and few other lectins in the elucidation of fucosyltransferase activities resembling cloned FT VI and apparently unique to colon cancer cells	Carbohydr. Res.	338	887-901	2003	Homo sapiens	● PubMed	<b>BRENDA</b>
<b>661803</b>	Abe, H.; Ohba, M.; Shimma, Y.-I.; Jigami, Y.	Yeast cells harboring human alpha-1,3-fucosyltransferase at the cell surface engineered using Pir, a cell wall-anchored protein	FEMS Yeast Res.	4	417-425	2004	Homo sapiens	● PubMed	<b>BRENDA</b>
<b>661839</b>	Dupuy, F.; Germot, A.; Julien, R.; Maftah, A.	Structure/function study of Lewis alpha3- and alpha3/4-fucosyltransferases: the alpha1,4 fucosylation requires an aromatic residue in the acceptor-binding domain	Glycobiology	14	347-356	2004	Homo sapiens, Gorilla gorilla, Pongo pygmaeus, Hylobates lar	● PubMed	<b>BRENDA</b>
<b>661845</b>	Leonard, R.; Lhemould, S.; Carlie, M.; Fleurat, P.; Maftah, A.; Costa, G.	Biochemical characterization of Silene alba alpha4-fucosyltransferase and Lewis a products	Glycoconj. J.	22	71-78	2005	Silene alba	● PubMed	<b>BRENDA</b>
<b>662137</b>	Ma, B.; Wang, G.; Palcic, M.M.; Hazes, B.; Taylor, D.E.	C-terminal amino acids of Helicobacter pylori alpha1,3/4	J. Biol. Chem.	278	21893-21900	2003	Helicobacter pylori	● PubMed	<b>BRENDA</b>

		<b>fucosyltransferases determine type I and type II transfer</b>							
<b>662484</b>	Morais, V.A.; Costa, J.	Stable expression of J. recombinant human alpha3/4 fucosyltransferase III in Spodoptera frugiperda Sf9 cells	Biotechnol.	106	69-75	2003	Homo sapiens	● <b>PubMed</b>	<b>BRENDA</b>

**LINKS TO OTHER DATABASES (specific for EC-Number 2.4.1.65)**

**ExPASy**

**KEGG**

NCBI: **PubMed**, **Protein**, **Nucleotide**, **Structure**, **Genome**, **OMIM**, **Domains**

**IUBMB Enzyme Nomenclature**

**PDB database(3D structure)**

**PROSITE Database of protein families and domains**

**SYSTEMS**

**Protein Mutant Database**

**Structural Classification of Proteins (SCOP)**

**Protein Structure Classification (CATH)**

**InterPro (database of protein families, domains and functional sites)**